menu
The continuous manufacturing market is projected to grow at an annualized rate of over 15%, till 2030::Roots
The continuous manufacturing market is projected to grow at an annualized rate of over 15%, till 2030::Roots
The continuous manufacturing market is projected to grow at an annualized rate of over 15%, till 2030

The continuous manufacturing market is projected to grow at an annualized rate of over 15%, till 2030

Roots Analysis has done a detailed study on ContinuousManufacturing Market (Small Molecules and Biologics), 2020 – 2030. covering keyaspects of the industry and identifying future growth opportunities.

 

To order this 310+ page report, which features 110+ figuresand 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

 

Key Market Insights

§  Eminentrepresentatives from prominent contract service provider companies /organizations are both optimistic and cautious regarding the rising interest incontinuous flow technologies, and its adoption

§  Over 60 companiesacross the globe claim to manufacture drug products / drug substances using thecontinuous manufacturing technique, either for in-house requirements or forcontract service engagements

§  The market landscapefeatures the presence of several well-established players, most of which claimto manufacture small molecules via the continuous technique, and are based inthe developed geographies

§  Companies have established continuous drug manufacturing facilities fordiverse types of dosage forms in various geographies; Europe and North Americahave emerged as the key hubs for these facilities

§  Several patents havebeen filed / granted specifically related to continuous manufacturing ofpharmaceutical substances, both industry and non-industry players are activelyinvolved in such efforts

§  Organizations havealso extended financial support to aid the research efforts being put byvarious stakeholders in this domain; the current focus is on investigation ofcontinuous manufacturing technologies

§  Over time, there has been a lot of activity in this arena, including theestablishment of several partnerships and investments in capability andcapacity expansions and new facilities worldwide

§  Most of thecontinuous manufacturing capacity belongs to established companies (in-housemanufacturers and CMOs), accounting for over 70% of the available capacityacross various geographies

§  Involvement of various other stakeholders including continuous equipmentproviders and modular facility providers is likely to revolutionize the overallmanufacturing domain

§  As the adoption ofcontinuous manufacturing technologies increases, the market is likely towitness significant growth; in the short term, majority of service-basedrevenues is likely to come from drug product related projects

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

 

Table of Contents

 

TABLEOF CONTENTS

 

1.         PREFACE        

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines

 

2.         EXECUTIVE SUMMARY

 

3.         INTRODUCTION

3.1.       Chapter Overview

3.2.       Historical Evolution of ContinuousManufacturing

3.3.       Continuous Manufacturing in thePharmaceutical Industry

3.3.1.    Regulatory Landscape

3.3.2.    Early Adopters of Continuous Manufacturing

3.3.3.    Anticipated Shift to ContinuousManufacturing

3.3.4.    Advantages of Continuous Manufacturing

3.3.5.    Key Challenges Associated with ContinuousManufacturing

3.3.6.    Future Perspectives

 

4.         MARKET LANDSCAPE

4.1.       Chapter Overview

4.2.       Companies with Expertise in ContinuousManufacturing: Overall Market Landscape

4.2.1.    Analysis by Year of Establishment

4.2.2.    Analysis by Company Size

4.2.3.    Analysis by Purpose of Manufacturing

4.2.4.    Analysis by Scale of Operation

4.2.5.    Analysis by Location of Headquarters

4.2.6.    Analysis by Location of ContinuousManufacturing Facilities

4.2.7.    Analysis by Type of Drug Molecule

4.2.8.    Analysis by Type of Continuous ManufacturingRelated Service

4.2.9.    Analysis by Type of Dosage Form

4.2.10.  Heat Map: Analysis by Company Size andLocation of Headquarters

4.2.11.  Information on Production Capacity

4.2.12.  Logo Landscape: Analysis by Year ofEstablishment and Company Size 

4.2.13.  Grid Representation: Analysis by Scale ofOperation, Type of Continuous Manufacturing Related Service and Type of DosageForm

4.2.14.  Geographical Map: Analysis by Location of ContinuousManufacturing Facilities and Type of Drug Molecule

 

5.         COMPANIES WITH EXPERTISE IN CONTINUOUSMANUFACTURING IN NORTH AMERICA: PROFILES

5.1.       Chapter Overview

5.2.       AbbVie Contract Manufacturing

5.2.1.    Company Overview

5.2.2.    Service Portfolio

5.2.3.    Continuous Manufacturing Capabilities andFacilities

5.2.4.    Recent Developments and Future Outlook

 

5.3.       Cambrex

5.3.1.    Company Overview

5.3.2.    Service Portfolio

5.3.3.    Continuous Manufacturing Capabilities andFacilities

5.3.4.    Recent Developments and Future Outlook

 

5.4.       Patheon

5.4.1.    Company Overview

5.4.2.    Service Portfolio

5.4.3.    Continuous Manufacturing Capabilities andFacilities

5.4.4.    Recent Developments and Future Outlook

 

5.5.       SK biotek

5.5.1.    Company Overview

5.5.2.    Service Portfolio

5.5.3.    Continuous Manufacturing Capabilities andFacilities

5.5.4.    Recent Developments and Future Outlook

 

6.         COMPANIES WITH EXPERTISE IN CONTINUOUSMANUFACTURING IN EUROPE: PROFILES

6.1.       Chapter Overview

6.2.       Ajinomoto Bio-Pharma Services

6.2.1.    Company Overview

6.2.2.    Service Portfolio

6.2.3.    Continuous Manufacturing Capabilities andFacilities

6.2.4.    Recent Developments and Future Outlook

 

6.3.       Almac

6.3.1.    Company Overview

6.3.2.    Service Portfolio

6.3.3.    Continuous Manufacturing Capabilities andFacilities

6.3.4.    Recent Developments and Future Outlook

 

6.4.       Boehringer Ingelheim BioXcellence™

6.4.1.    Company Overview

6.4.2.    Service Portfolio

6.4.3.    Continuous Manufacturing Capabilities andFacilities

6.4.4.    Recent Developments and Future Outlook

 

6.5.       CordonPharma

6.5.1.    Company Overview

6.5.2.    Service Portfolio

6.5.3.    Continuous Manufacturing Capabilities andFacilities

6.5.4.    Recent Developments and Future Outlook

 

6.6.       Hovione

6.6.1.    Company Overview

6.6.2.    Service Portfolio

6.6.3.    Continuous Manufacturing Capabilities andFacilities

6.6.4.    Recent Developments and Future Outlook

 

6.7.       Lonza

6.7.1.    Company Overview

6.7.2.    Service Portfolio

6.7.3.    Continuous Manufacturing Capabilities andFacilities

6.7.4.    Recent Developments and Future Outlook

 

7.         COMPANIES WITH EXPERTISE IN CONTINUOUSMANUFACTURING IN ASIA-PACIFIC: PROFILES

7.1.       Chapter Overview

7.2.       Kaneka

7.2.1.    Company Overview

7.2.2.    Service Portfolio

7.2.3.    Continuous Manufacturing Capabilities andFacilities

7.2.4.    Recent Developments and Future Outlook     

 

7.3.       WuXi AppTec

7.3.1.    Company Overview

7.3.2.    Service Portfolio

7.3.3.    Continuous Manufacturing Capabilities andFacilities

7.3.4.    Recent Developments and Future Outlook                 

 

8.         RECENT PARTNERSHIPS AND COLLABORATIONS

8.1.       Chapter Overview

8.2.       Partnership Models

8.3.       List of Partnerships and Collaborations

8.3.1.    Analysis by Year of Partnership

8.3.2.    Analysis by Type of Partnership

8.3.3.    Analysis by Scale of Operation

8.3.4.    Analysis by Type of Drug Molecule

8.3.5.    Analysis by Type of Continuous ManufacturingRelated Service

8.3.6.    Analysis by Type of Dosage Form

8.3.7.    Most Active Players: Analysis by Number ofPartnerships

 

8.3.8.    Regional Analysis

8.3.8.1. Intercontinental and IntracontinentalAgreements

 

9.         RECENT EXPANSIONS

9.1.       Chapter Overview

9.2.       Recent Expansions

9.2.1.    Analysis by Year of Expansion

9.2.2.    Analysis by Type of Expansion

9.2.3.    Analysis by Expanded Scale of Expansion

9.2.4.    Analysis by Type of Drug Molecule

9.2.5.    Analysis by Type of Continuous ManufacturingRelated Service

9.2.6.    Analysis by Type of Dosage Form

9.2.7.    Most Active Players: Analysis by Number ofExpansions

 

9.2.8.    Regional Analysis

9.2.8.1. Analysis by Location of Expansion Project

 

10.        CAPACITY ANALYSIS

10.1.     Chapter Overview

10.2.     Assumptions and Methodology

10.3.     Global, Continuous Manufacturing Capacityfor Small Molecule APIs

10.3.1.  Analysis by Company Size

10.3.2. Analysis by Purpose of Manufacturing

10.3.3.  Analysis by Scale of Operation

10.3.4.  Analysis by Location of Headquarters

10.3.4.  Analysis by Location of ContinuousManufacturing Facilities

 

10.4.     Global, Continuous Manufacturing Capacityfor Small Molecule End Products

10.4.1.  Analysis by Company Size

10.4.2. Analysis by Purpose of Manufacturing

10.4.3.  Analysis by Scale of Operation

10.4.4.  Analysis by Location of Headquarters

10.4.5.  Analysis by Location of ContinuousManufacturing Facilities

 

10.5.     Global, Continuous Manufacturing Capacityfor Biologic

10.5.1.  Analysis by Company Size

10.5.2. Analysis by Purpose of Manufacturing

10.5.3.  Analysis by Scale of Operation

10.5.4.  Analysis by Location of Headquarters

10.5.5.  Analysis by Location of ContinuousManufacturing Facilities

 

11.       ACADEMIC GRANT ANALYSIS

11.1.     Chapter Overview

11.2.     Scope and Methodology

11.3.     Continuous Manufacturing: List of AcademicGrants

11.3.1.  Analysis by Number of Grants

11.3.2.  Analysis by Activity Code

11.3.3.  Analysis by Grant Amount

11.3.4.  Analysis by Focus Area

11.3.5.  Analysis by Support Period

11.3.6   Popular Recipient Organizations: Analysis byNumber of Grants

11.3.7   Analysis by Type of Recipient Organization

11.3.8.  Analysis by Funding Institute Centre

11.3.9.  Analysis by Funding Mechanism

11.3.10.Prominent Program Officers: Analysis by Number of Grants

 

12.       PATENT ANALYSIS

12.1.     Chapter Overview

12.2.     Scope and Methodology

12.3.     Continuous Manufacturing: Patent Analysis

12.3.1.  Analysis by Publication Year

12.3.2.  Analysis by Geography

12.3.3.  Analysis by CPC Symbols

12.3.4.  Emerging Focus Areas

12.3.5.  Analysis by Type of Applicant

12.3.6.  Leading Players: Analysis by Number of Patents

12.3.7.  Continuous Manufacturing: Three-DimensionalBubble Analysis

12.3.8.  Continuous Manufacturing: Patent ValuationAnalysis

12.3.8.1.Leading Patents: Information by Number of Citations

 

13.        INITIATIVES OF COMPANIES WITH IN-HOUSECONTINUOUS MANUFACTURING CAPABILITIES

13.1.     Chapter Overview

13.2.     Continuous Manufacturing Initiatives ofLeading Companies

13.2.1.  AbbVie

13.2.1.1.Partnered Initiatives

13.2.1.2In-House Initiatives

 

13.2.2.  Amgen

13.2.2.1.Partnered Initiatives

13.2.2.2.In-House Initiatives

 

13.2.3.  Bristol-Myers Squibb

13.2.3.1.Partnered Initiatives

13.2.3.2.In-House Initiatives

 

13.2.4.  GlaxoSmithKline

13.2.4.1.Partnered Initiatives

13.2.4.2.In-House Initiatives

 

13.2.5.  Merck

13.2.5.1.Partnered Initiatives

13.2.5.2.In-House Initiatives

 

13.2.6.  Novartis

13.2.6.1.Partnered Initiatives

13.2.6.2.In-House Initiatives

 

13.2.7.  Pfizer

13.2.7.1.Partnered Initiatives

13.2.7.2.In-House Initiatives

 

13.2.8.  Roche

13.2.8.1.Partnered Initiatives

13.2.8.2.In-House Initiatives

13.2.9.  Sanofi

13.2.9.1.Partnered Initiatives

13.2.9.2.In-House Initiatives

 

14.        CASE STUDY: MODULAR FACILITIES INPHARMACEUTICAL / BIOTECHNOLOGY INDUSTRY

14.1.     Chapter Overview

14.2.     Historical Background

14.3.     Concept of Modularization

14.3.1.  Types of Modules

14.3.2.  Modular Construction Process

 

14.4.     Modular Construction in the PharmaceuticalIndustry

14.4.1.  Advantages of Modular Construction in thePharmaceutical Industry

 

14.5.     Modular Facility Manufacturers

14.5.1.  Distribution by Industry Served

14.5.2.  Distribution by Geography

14.5.3.  Modular Projects Executed / Undertaken

 

14.6.     Modular Pharmaceutical Cleanrooms

14.6.1.  Cleanroom Classification and Current Standards

14.6.2.  Advantages of Modular Cleanrooms

14.6.3.  Regulations and Standards Concerning ModularCleanroom Construction

 

14.7.     Modular Cleanroom Providers

14.7.1.  Distribution by Industry Served

14.7.2.  Distribution by Geography

14.7.3.  Type of Modular Cleanrooms Offered

 

15.       CASE STUDY: TECHNOLOGY ANDEQUIPMENT PROVIDERS

15.1.     Chapter Overview

15.2.     Types of Continuous ManufacturingTechnologies

15.3.     Equipment and Technologies for ContinuousManufacturing Small Molecules and Biologics

15.3.1.  Continuous Blending and Mixing Equipment

15.3.2.  Continuous Granulating Equipment

15.3.3.  Continuous Drying Equipment

15.3.4.  Continuous Compression Equipment

15.3.5.  Continuous Coating Equipment

15.3.6.  Continuous Filtration, Continuous Distillationand Continuous Centrifugation Equipment

15.3.7.  Continuous Chromatography Equipment

15.3.8.  Continuous Reactors / Bioreactors

15.3.9.  Full Line Continuous Platforms

15.3.10.Process Analytical Technologies

15.3.11.Other Technologies

15.4.     Logo Landscape: Analysis of TechnologyProviders by Number and Type of Equipment

 

16.        CASE STUDY: ROADMAP FOR THE ADOPTION OFCONTINUOUS MANUFACTURING PROCESSES

16.1.     Chapter Overview

16.2.     Key Strategies for the Adoption ofContinuous Manufacturing Processes

16.2.1. Phase I: Process Development andImplementation

16.2.2. Phase II: Equipment / TechnologyDevelopment and Installation

16.2.3. Phase III: Facility / Plant Developmentand Establishment

16.2.4. Phase IV: Product Development andManufacturing

 

17.       MARKET FORECAST AND OPPORTUNITYANALYSIS

17.1.     Chapter Overview

17.2.     Forecast Methodology and Key Assumptions

17.3.     Overall, Continuous Manufacturing Market,2020-2030

17.3.1.  Continuous Manufacturing Market: Distributionby Purpose of Manufacturing, 2020-2030

17.3.2.  Continuous Manufacturing Market: Distributionby Scale of Operation, 2020-2030

17.3.3.  Continuous Manufacturing Market: Distributionby Type of Drug Molecule, 2020-2030

17.3.4.  Continuous Manufacturing Market: Distributionby Type of Continuous Manufacturing Related Service, 2020-2030

17.3.5.  Continuous Manufacturing Market: Distributionby Type of Dosage Form, 2020-2030

17.3.6.  Continuous Manufacturing Market: Distributionby Key Geographical Regions, 2020-2030

 

17.4.     Continuous Manufacturing Market for SmallMolecule, 2020-2030

17.4.1.  Distribution by Purpose of Manufacturing,2020-2030

17.4.2.  Distribution by Scale of Operation, 2020-2030

17.4.3.  Distribution by Type of ContinuousManufacturing Related Service, 2020-2030

17.4.4.  Distribution by Key Geographical Regions,2020-2030

 

17.5.     Continuous Manufacturing Market forBiologic, 2020-2030

17.5.1.  Distribution by Purpose of Manufacturing,2020-2030

17.5.2.  Distribution by Scale of Operation, 2020-2030

17.5.3.  Distribution by Type of ContinuousManufacturing Related Service, 2020-2030

17.5.4.  Distribution by Key Geographical Regions, 2020-2030

 

18.        CONCLUSION

18.1.     Chapter Overview

18.2.     Key Takeaways

 

19.        EXECUTIVE INSIGHTS

19.1.     Chapter Overview

19.2.     Zaiput Flow Technologies

19.2.1.  Company Snapshot

19.2.2.  Interview Transcript: Andrea Adamo, Founderand Chief Executive Officer

 

19.3.     CONTINUUS Pharmaceuticals

19.3.1.  Company Snapshot

19.3.2.  Interview Transcript: Bayan Takizawa,Co-Founder and Chief Business Officer

 

19.4.     Snapdragon Chemistry

19.4.1.  Company Snapshot

19.4.2.  Interview Transcript: Eric Fang, ChiefScientific Officer

 

19.5.     Enzene Biosciences

19.5.1.  Company Snapshot

19.5.2.  Interview Transcript: Himanshu Gadgil,Director and Chief Scientific Officer

 

19.6.     Pfizer

19.6.1.  Company Snapshot

19.6.2.  Interview Transcript: Nick Thomson, SeniorDirector Chemical Research and Development

19.7.     University of Strathclyde

19.7.1.  Company Snapshot

19.7.2.  Interview Transcript: Ian Houson, TechnicalProject Manager

 

 

20.        APPENDIX 1: TABULATED DATA

 

21.        APPENDIX 2: LIST OF COMPANIES ANDORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com